Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

Abstract In the primary analysis (32.3-month median follow-up) of the randomized, phase 3 AURIGA study (NCT03901963), daratumumab-lenalidomide (D-R) maintenance significantly improved MRD-negative conversion rates and reduced the risk of disease progression or death by 47% versus R maintenance in an...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Blood Cancer Journal
المؤلفون الرئيسيون:	Laahn Foster, Larry D. Anderson, Alfred Chung, Chakra P. Chaulagain, Erin Pettijohn, Andrew J. Cowan, Caitlin Costello, Sarah Larson, Douglas W. Sborov, Kenneth H. Shain, Rebecca Silbermann, Peter Voorhees, Maria Krevvata, Huiling Pei, Sharmila Patel, Vipin Khare, Annelore Cortoos, Robin Carson, Thomas S. Lin, Ashraf Badros
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Nature Publishing Group 2025-10-01
الوصول للمادة أونلاين:	https://doi.org/10.1038/s41408-025-01355-0